Low Antithrombin III in Morbid Obesity: Return to Normal with Weight Reduction

Abstract

Morbidly obese adults are at increased risk for perioperative thrombotic complications. Antithrombin III (AT III) is a major endogenous anticoagulant and its deficiency is associated with more frequent thrombotic diseases. We measured AT III quantity and function in 23 morbidly obese adults and in 19 otherwise identical people who had reduced their mean weight to 160% of ideal body weight. Both groups were compared to normal weight controls (<120% ideal body weight). Serum and plasma AT III function and serum AT III antigenic concentration were significantly lower in the morbidly obese people compared to the weight reduced group in all three assays. The reduced group had values within the normal range of the normal weight group. In addition, three patients studied both before and after weight loss had similar significant changes in their AT III. We conclude that AT III is reduced in morbidly obese adults and normalizes as weight is reduced. Possible mechanisms of this deficiency and therapeutic approaches are considered. (Journal of Parenteral and Enteral Nutrition 7:447-449, 1983

Get full access to this article

View all access options for this article.

References

Drenick EJ , Bale GS , Seltzer F. , et al: Excessive mortality and causes of death in morbidly obese men . JAMA 243:443-445, 1980

Printen KJ , Mason EE : Gastric surgery for relief of morbid obesity. Arch Surg 111:398-402, 1976

Mason EE , Gordy DD , Chevingoy FA , et al: Fatty acid toxicity. Surg Gynecol Obstet 133:992-998, 1971

Printen KJ , Miller EV , Mason EE , et al: Venous thromboembolism in the morbidly obese. Surg Gynecol Obstet 147:63-64, 1978

Golrick RB : Obesity and fibrinolysis in Australian and New Guinea men. Aust Ann Med 10:20, 1961

Abilgaard U. : Evidence that antithrombin III is the main physiological inhibitor of coagulation enzyme. IN The Physiological Inhibitors of Coagulation and Fibrinolysin. Collen D , Wilman B , Verstaete M , eds). Elsevier/ North Holland, Biomedical Press, New York, 1972

Abilgaard U. : Review of antithrombin III. IN The Physiological Inhibitors of Coagulation and Fibrinolysin. Collen, D , Wilman B , Verstaete, M , (eds). Elsevier / North Holland, Biomedical Press, New York, 1972

Karl R. , Garlick I. , Zarius C. , et al: Surgical implications of antithrombin III deficiency. Surgery 89 4:429-435, 1981

Von Kaulla E. : Antithrombin III and diseases. Am J Clin Pathol 48:69-80, 1967

10.

Abilgaard U. , Lie N. , Odegard OR : Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2288 and chromozym TH) . Thromb Res 11:549-553, 1977

11.

Egeberg V. : Inherited anthrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13:516-530, 1965

12.

Mancini G. , Carbonawa AG , Havemans JF : Immunochemical quantitation of antigens by single radial immuno-diffusion . Immuno-chemistry 2:235-238, 1965

13.

Von Kaulla E. , Von Kaulla KN : Oral contraceptives and low antithrombin III activity. Lancet 1:36, 1970

14.

Fagerhol MK , Abilgaard U. , Bergsjo P. , et al: Oral contraceptives and low antithrombin III concentration. Lancet 1:1175, 1970

15.

Sims EAH , Danforth EH , Horton ES , et al: Endocrine and metabolic effects of experimental obesity in men . Recent Prog Horm Res 29:457-487, 1973

16.

Schneider G. , Kirschner MA , Berkowitz R. , et al: Increased estrogen production in obese men. J Clin Endocrinol Metab 48:633-638, 1969

17.

Heimburger N. : Inactivation of antithrombin III by fatty acids. Hoppe-Seyler's Z Physiol Chem 353:1957-1961, 1972

18.

Marciniak E. , Farley CH , DeSimone PA : Familial thrombosis due to antithrombin III deficiency. Blood 43:219-231, 1974

19.

Nilsen DWT , Jeremic M. , Weisert OK : An attempt at predicting post-operative deep vein thrombosis by preoperative coagulation studies in patients undergoing total hip replacement. Thrombos Haematosis 43:194-197, 1980